ReNeuron has announced its FY’20 prelim results for the 12-month period ending 31 March 2020. In the period, Revenue & other income for the period was £6.1m (vs. £0.0 in September 2019), principally made up of £6.0m received from Fosun Pharma as an initial gross license fee. We expect smaller milestones payments from Fosun Pharma in FY’21 and FY’22. R&D expenditure of £16.3m (vs. £16.2m prior year; vs. historic N+1 Singer estimate of &po
20 Jul 2020
ReNeuron FY’20 prelims
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
ReNeuron FY’20 prelims
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
20 Jul 2020 -
Author:
Edward Thomason -
Pages:
3
ReNeuron has announced its FY’20 prelim results for the 12-month period ending 31 March 2020. In the period, Revenue & other income for the period was £6.1m (vs. £0.0 in September 2019), principally made up of £6.0m received from Fosun Pharma as an initial gross license fee. We expect smaller milestones payments from Fosun Pharma in FY’21 and FY’22. R&D expenditure of £16.3m (vs. £16.2m prior year; vs. historic N+1 Singer estimate of &po